GO:0090208 positive regulation of triglyceride metabolic process: Lipid Homeostasis Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0090208 describes any biological process that increases the frequency, rate, or extent of triglyceride metabolism, a central node in energy storage and cardiometabolic disease.
• Triglyceride metabolism is positively regulated by hormonal signals, transcription factors such as SREBP-1c, and enzymes including glycerol kinase and DGAT1/2.
• Dysregulation of triglyceride metabolic process contributes to nonalcoholic fatty liver disease, coronary artery disease, and diabetes.
• The triglyceride-glucose index is a validated surrogate marker for insulin resistance and cardiovascular risk, reflecting the clinical importance of this pathway.
• Key experimental models include hepatocyte-specific knockout of Gk, overexpression of Angptl3, and knock-in of patient-derived mutations in SREBF1 or DGAT1.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable causal dissection of genes that positively regulate triglyceride metabolism.
Description
Triglycerides are neutral lipids composed of a glycerol backbone esterified with three fatty acids, and their metabolic process encompasses synthesis, storage, lipolysis, and oxidation. The Gene Ontology term GO:0090208, positive regulation of triglyceride metabolic process, refers to any process that increases the frequency, rate, or extent of the chemical reactions and pathways involving triglycerides. This term is critical for researchers because triglyceride homeostasis is tightly linked to energy balance, insulin sensitivity, and cardiovascular health. Perturbations in positive regulators of triglyceride metabolism are observed in chronic liver disease, nonalcoholic fatty liver disease (NAFLD), and coronary artery disease. Understanding these regulators at the molecular level provides mechanistic insights and therapeutic targets. Experimental models, including CRISPR-engineered cells and animals, are essential to establish causality and to test interventions.
positive regulation of triglyceride metabolic process At A Glance
| GO ID | GO:0090208 |
|---|---|
| GO term | positive regulation of triglyceride metabolic process |
| Ontology | biological_process |
| Synonym | none |
| Major function | Increases the rate or extent of triglyceride synthesis, storage, or utilization |
| Key regulators | SREBP-1c, glycerol kinase, DGAT1/2, ANGPTL3, insulin signaling |
| Associated diseases | NAFLD, coronary artery disease, diabetes, chronic liver disease |
| Research methods | CRISPR KO/KI, overexpression, lipidomics, RNA-seq, ChIP-seq |
What Is GO:0090208?
GO:0090208 is a biological process term defined as any process that increases the frequency, rate, or extent of the chemical reactions and pathways involving triglyceride, any triester of glycerol. In practice, this includes signaling events, transcriptional activation, and enzymatic steps that enhance triglyceride synthesis, lipid droplet formation, or lipid storage, as well as processes that promote the breakdown and utilization of triglycerides when energy demand increases.
Why Is positive regulation of triglyceride metabolic process Important in Cell Biology?
Positive regulation of triglyceride metabolic process is fundamental to whole-body energy homeostasis. When this regulation is excessive, it drives hepatic steatosis, hypertriglyceridemia, and atherosclerosis; when it is insufficient, it contributes to lipodystrophy and metabolic inflexibility. The clinical relevance is underscored by the triglyceride-glucose index, which predicts coronary artery disease severity and cardiometabolic risk across glucose metabolism states. Moreover, somatic mutations in metabolism genes, including those affecting lipid handling, are enriched in chronic liver disease, highlighting the pathway's role in disease progression. Therefore, understanding the positive regulators of triglyceride metabolism is essential for developing targeted therapies.
• Central to energy storage and mobilization in adipose tissue and liver.
• Dysregulation causes nonalcoholic fatty liver disease and hypertriglyceridemia.
• ANGPTL3 inhibition lowers triglycerides and is a therapeutic strategy.
• Triglyceride-glucose index predicts coronary artery disease severity.
• Somatic mutations in metabolism genes are linked to chronic liver disease.
• Glycerol kinase drives de novo lipogenesis and triglyceride synthesis via SREBP-1c.
• Taurine supplementation alters lipid metabolism in hypothyroidism models.
• Experimental models of metabolic disorders reveal dynamic regulation of triglyceride metabolism.
• Cholesterol-HDL-glucose index and triglyceride-glucose index are comparative risk markers.
• CRISPR screening identifies novel regulators of lipid storage and breakdown.
What Happens During positive regulation of triglyceride metabolic process?
Transcriptional activation of lipogenic genes
In simple terms: The cell turns on genes that make fat.
Positive regulation often begins with transcriptional activation of genes involved in fatty acid synthesis and triglyceride assembly. SREBP-1c is a master transcription factor that upregulates DGAT1 and DGAT2, enzymes that catalyze the final step of triglyceride synthesis. Glycerol kinase (GK) promotes glycerol metabolism and activates SREBP-1c transcription, thereby driving de novo lipogenesis and triglyceride synthesis in NAFLD. This transcriptional program increases the capacity for triglyceride production.
Hormonal and signaling inputs
In simple terms: Hormones tell the body to store or burn fat.
Insulin signaling promotes triglyceride storage by activating lipogenic transcription and inhibiting lipolysis. ANGPTL3 is a liver-derived protein that inhibits lipoprotein lipase and endothelial lipase, thereby increasing circulating triglycerides; its inhibition lowers triglyceride levels. Conversely, lipolytic hormones such as catecholamines stimulate triglyceride breakdown, which can be considered positive regulation of the catabolic arm of triglyceride metabolism.
Enzymatic steps in triglyceride synthesis
In simple terms: Enzymes build triglycerides from building blocks.
Triglyceride synthesis requires glycerol-3-phosphate acyltransferases (GPATs), acylglycerol-3-phosphate acyltransferases (AGPATs), phosphatidate phosphatase (PAP), and diacylglycerol acyltransferases (DGAT1/2). DGAT1 and DGAT2 catalyze the final esterification step, and their upregulation by SREBP-1c directly increases triglyceride production. Glycerol kinase provides glycerol-3-phosphate from glycerol, linking glycerol metabolism to triglyceride synthesis.
Lipid droplet formation and storage
In simple terms: The cell packages fat into droplets.
Once synthesized, triglycerides are stored in lipid droplets. Positive regulation of triglyceride metabolism includes the expansion of lipid droplet number and size, which is observed in hepatocytes and adipocytes under lipogenic conditions. This storage form is dynamic and can be mobilized by lipases when energy is needed.
Lipolysis and fatty acid oxidation
In simple terms: The cell breaks down fat for energy.
Positive regulation also encompasses the catabolic arm: activation of adipose triglyceride lipase (ATGL), hormone-sensitive lipase (HSL), and monoacylglycerol lipase (MGL) increases the rate of triglyceride hydrolysis, releasing free fatty acids and glycerol. These fatty acids can then undergo beta-oxidation. Thus, the term covers both anabolic and catabolic processes that increase overall triglyceride metabolic flux.
Key Genes Involved in GO:0090208 positive regulation of triglyceride metabolic process
The following genes and proteins are established positive regulators or core components of triglyceride metabolic process, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SREBF1 (SREBP-1c) | Master transcription factor for lipogenic genes | Upregulates DGAT1/2 and promotes triglyceride synthesis |
| GK | Glycerol kinase; provides glycerol-3-phosphate | Drives de novo lipogenesis and SREBP-1c activation |
| DGAT1 | Diacylglycerol acyltransferase 1 | Catalyzes final step of triglyceride synthesis |
| DGAT2 | Diacylglycerol acyltransferase 2 | Catalyzes final step of triglyceride synthesis |
| ANGPTL3 | Inhibits lipoprotein lipase and endothelial lipase | Increases circulating triglycerides; therapeutic target |
| LPL | Lipoprotein lipase; hydrolyzes plasma triglycerides | Key enzyme for triglyceride clearance |
| ATGL (PNPLA2) | Adipose triglyceride lipase | Rate-limiting for lipolysis |
| HSL (LIPE) | Hormone-sensitive lipase | Diacylglycerol and triglyceride hydrolysis |
| MGL (MGLL) | Monoacylglycerol lipase | Final step of lipolysis |
| GPAM | Glycerol-3-phosphate acyltransferase | First step of triglyceride synthesis |
| AGPAT2 | Acylglycerol-3-phosphate acyltransferase | Second step of triglyceride synthesis |
| PAP (LPIN1) | Phosphatidate phosphatase | Generates diacylglycerol for DGAT |
| INSR | Insulin receptor | Mediates insulin-stimulated lipogenesis |
| AKT2 | Serine/threonine kinase | Downstream of insulin; promotes lipogenesis |
| FOXO1 | Forkhead transcription factor | Inhibited by insulin; reduces lipolysis |
| PPARG | Peroxisome proliferator-activated receptor gamma | Promotes adipocyte differentiation and lipid storage |
| CIDEC | Cell death-inducing DFFA-like effector c | Lipid droplet fusion and enlargement |
How Is positive regulation of triglyceride metabolic process Regulated?
Positive regulation of triglyceride metabolic process is controlled at multiple levels. Insulin signaling through INSR/AKT2 activates SREBP-1c and inhibits FOXO1, promoting lipogenesis and suppressing lipolysis. Glycerol kinase enhances SREBP-1c transcription and upregulates DGAT1/2, creating a feed-forward loop. ANGPTL3 is regulated by nutritional status and hormones; its inhibition increases lipoprotein lipase activity and lowers triglycerides. In chronic liver disease, somatic mutations in metabolism genes, including those in lipid pathways, may alter regulatory networks. Experimental models of metabolic disorders show dynamic changes in these regulators over time.
positive regulation of triglyceride metabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GK | NAFLD, hepatic steatosis | Liver-specific Gk knockout or overexpression in mice |
| ANGPTL3 | Hypertriglyceridemia, diabetes | Angptl3 knockout or overexpression in mice |
| DGAT1 | Lipid metabolism disorders | Dgat1 knockout or knock-in in hepatocytes |
| SREBF1 | NAFLD, insulin resistance | Inducible Srebp-1c transgenic mice |
| PNPLA2 (ATGL) | Lipodystrophy, cardiomyopathy | Pnpla2 knockout mice |
Nonalcoholic fatty liver disease (NAFLD)
NAFLD is characterized by excessive hepatic triglyceride accumulation. Glycerol kinase drives de novo lipogenesis and triglyceride synthesis by activating SREBP-1c and upregulating DGAT1/2, making it a potential therapeutic target. Somatic mutations in metabolism genes are enriched in chronic liver disease, further implicating dysregulated triglyceride metabolism in disease progression.
Coronary artery disease and cardiometabolic risk
Elevated triglycerides are a risk factor for coronary artery disease. The triglyceride-glucose index, a surrogate marker of insulin resistance, is associated with coronary artery disease severity across different glucose metabolism states. A comparative study of cholesterol-HDL-glucose index and triglyceride-glucose index highlights their utility in anticipating cardiometabolic diseases.
Diabetes and insulin resistance
ANGPTL3 plays a role in triglyceride regulation, glucose homeostasis, and diabetes. Insulin resistance impairs the suppression of lipolysis and increases hepatic triglyceride production, contributing to hypertriglyceridemia. Experimental models of metabolic disorders reveal dynamic regulation of these pathways.
Hypothyroidism and lipid metabolism
Hypothyroidism is associated with dyslipidemia. High-dose taurine supplementation increases serum paraoxonase and arylesterase activities in experimental hypothyroidism, indicating a link between thyroid status and lipid metabolism. This suggests that positive regulation of triglyceride metabolism can be modulated by nutritional and hormonal factors.
From positive regulation of triglyceride metabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X positively regulate triglyceride synthesis? | CRISPR knockout in HepG2 or primary hepatocytes |
| Does a point mutation in DGAT1 alter enzyme activity? | CRISPR point mutation knock-in in cell lines |
| Does overexpression of ANGPTL3 increase plasma triglycerides? | AAV-mediated overexpression in mice |
| Does a tagged version of SREBP-1c localize to lipid droplets? | CRISPR knock-in of fluorescent tag |
| Does gene X affect lipolysis rate? | CRISPR knockout in adipocytes followed by lipolysis assay |
| Does a patient-derived mutation in GK cause steatosis? | Knock-in mouse model |
How to Study the positive regulation of triglyceride metabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Lipidomics (LC-MS) | Triglyceride species and abundance | Quantify steatosis in knockout cells |
| RNA-seq | Gene expression changes | Identify lipogenic program activation |
| ChIP-seq | Transcription factor binding | Map SREBP-1c targets |
| CRISPR screen | Genes affecting triglyceride levels | Discover novel regulators |
| Isotope tracing | De novo lipogenesis flux | Measure glycerol incorporation |
| Lipolysis assay | Free glycerol/fatty acid release | Assess catabolic regulation |
| Western blot | Protein expression and phosphorylation | Validate signaling changes |
| Immunofluorescence | Lipid droplet morphology | Visualize storage changes |
Lipidomics and triglyceride quantification
Mass spectrometry-based lipidomics enables precise measurement of triglyceride species in cells and tissues. This method is essential to quantify changes in triglyceride levels upon genetic manipulation.
Transcriptomics and ChIP-seq
RNA-seq identifies changes in lipogenic gene expression, while ChIP-seq can map SREBP-1c binding to target promoters such as DGAT1/2. These approaches reveal transcriptional mechanisms of positive regulation.
CRISPR screening
Genome-wide CRISPR knockout or activation screens can identify novel positive regulators of triglyceride metabolism. Such screens have uncovered genes involved in lipid storage and breakdown.
Metabolic flux analysis
Isotope tracing with 13C-glycerol or 13C-acetate measures de novo lipogenesis and triglyceride synthesis flux. This method directly assesses the rate of triglyceride metabolic process.
How CRISPR Can Be Used to Study GO:0090208 positive regulation of triglyceride metabolic process
Knockout
CRISPR knockout of candidate genes such as Gk or Dgat1 in hepatocytes or adipocytes can determine whether they are required for positive regulation of triglyceride metabolism. Loss of function typically reduces triglyceride synthesis or storage.
Point Mutation
Point mutations identified in patient cohorts can be introduced via CRISPR base editing or homology-directed repair to test their impact on enzyme activity and triglyceride flux. For example, mutations in DGAT1 may alter catalytic efficiency.
Knock-in
Knock-in of fluorescent or epitope tags allows visualization and purification of proteins such as SREBP-1c or DGAT2, enabling localization and interaction studies in the context of triglyceride metabolism.
Overexpression
CRISPR activation (CRISPRa) or cDNA overexpression can drive supraphysiological expression of positive regulators like ANGPTL3 or glycerol kinase, leading to increased triglyceride levels and providing gain-of-function models.
How EDITGENE Supports positive regulation of triglyceride metabolic process Research
Researchers studying positive regulation of triglyceride metabolic process-related genes often need to determine whether a candidate gene is causally involved in lipid accumulation, how mutations affect enzyme function, and where the protein localizes within the cell. EDITGENE provides end-to-end CRISPR solutions to answer these questions with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of triglyceride metabolic process research.
Frequently Asked Questions About positive regulation of triglyceride metabolic process
What is GO:0090208?
GO:0090208 is the Gene Ontology term for positive regulation of triglyceride metabolic process, defined as any process that increases the frequency, rate, or extent of the chemical reactions and pathways involving triglycerides.
What genes are involved in positive regulation of triglyceride metabolic process?
Key genes include SREBF1 (SREBP-1c), GK, DGAT1, DGAT2, ANGPTL3, LPL, ATGL (PNPLA2), HSL (LIPE), and MGL (MGLL).
How is triglyceride metabolism regulated?
It is regulated by insulin signaling, transcription factors like SREBP-1c, and enzymes such as glycerol kinase and DGAT1/2, as well as by ANGPTL3 inhibition of lipases.
What diseases are associated with abnormal triglyceride metabolism?
Nonalcoholic fatty liver disease, coronary artery disease, diabetes, and chronic liver disease are associated with dysregulated triglyceride metabolism.
What is the triglyceride-glucose index?
The triglyceride-glucose index is a surrogate marker of insulin resistance that predicts coronary artery disease severity and cardiometabolic risk.
How can CRISPR be used to study triglyceride metabolism?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of genes in triglyceride synthesis, storage, and breakdown.
What is the role of glycerol kinase in triglyceride synthesis?
Glycerol kinase drives hepatic de novo lipogenesis and triglyceride synthesis by activating SREBP-1c transcription and upregulating DGAT1/2.
What is the function of ANGPTL3 in triglyceride metabolism?
ANGPTL3 inhibits lipoprotein lipase and endothelial lipase, increasing circulating triglycerides; its inhibition lowers triglyceride levels.
Which experimental models are used to study positive regulation of triglyceride metabolism?
Common models include liver-specific knockout mice, adipocyte cell lines, and CRISPR-engineered hepatocytes.
What methods measure triglyceride metabolic flux?
Lipidomics, isotope tracing, RNA-seq, ChIP-seq, and lipolysis assays are used to measure triglyceride levels and flux.
Conclusion
GO:0090208 positive regulation of triglyceride metabolic process is a central biological process that integrates hormonal, transcriptional, and enzymatic signals to control energy storage and mobilization. Its dysregulation is implicated in prevalent metabolic diseases, making it a prime target for therapeutic intervention. CRISPR-based models are indispensable for dissecting the causal roles of individual genes and for discovering new regulators. EDITGENE offers comprehensive services to support such research, from knockout and knock-in models to library screening and bioinformatics.
References
- 1. Cho CH et al.. 2023. Adipose tissue lipid metabolism: lipolysis.. Curr Opin Genet Dev 83:102114 PMID: 37738733
- 2. Ng SWK et al.. 2021. Convergent somatic mutations in metabolism genes in chronic liver disease.. Nature 598(7881):473-478 PMID: 34646017
- 3. Ouyang S et al.. 2024. Glycerol Kinase Drives Hepatic de novo Lipogenesis and Triglyceride Synthesis in Nonalcoholic Fatty Liver by Activating SREBP-1c Transcription, Upregulating DGAT1/2 Expression, and Promoting Glycerol Metabolism.. Adv Sci (Weinh) 11(46):e2401311 PMID: 39418169
- 4. Christopoulou E et al.. 2019. Effects of Angiopoietin-Like 3 on Triglyceride Regulation, Glucose Homeostasis, and Diabetes.. Dis Markers 2019:6578327 PMID: 30944669
- 5. Dirican M et al.. 2007. High-dose taurine supplementation increases serum paraoxonase and arylesterase activities in experimental hypothyroidism.. Clin Exp Pharmacol Physiol 34(9):833-7 PMID: 17645625
- 6. Shestopalov AV et al.. 2024. Features of Metabolism and Its Regulation in the Dynamics of Experimental Models of Metabolic Disorders.. Bull Exp Biol Med 178(2):280-286 PMID: 39760942
- 7. Zhao S et al.. 2024. Comprehensive analysis of the association between triglyceride-glucose index and coronary artery disease severity across different glucose metabolism states: a large-scale cross-sectional study from an Asian cohort.. Cardiovasc Diabetol 23(1):251 PMID: 39003471
- 8. Tang J et al.. 2025. Assessment of cholesterol-HDL-glucose index in anticipating risk of cardiometabolic diseases: a comparative study with triglyceride-glucose index.. Sci Rep 15(1):45356 PMID: 41291178
